Acorda Therapeutics
ACORDrugs in Pipeline
14
Phase 3 Programs
7
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
CVT-301
Idiopathic Parkinson's Disease
dalfampridine-ER 7.5mg
Post-Ischemic Stroke
Fampridine-SR
Multiple Sclerosis
Dalfampridine-ER 5mg
Multiple Sclerosis
CVT-301 Low Dose
Idiopathic Parkinson's Disease
Fampridine-SR b.i.d. (Twice Daily)
Multiple Sclerosis
Dalfampridine Pill
Multiple Sclerosis
Dalfampridine
Spinal Cord Injury
10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)
Multiple Sclerosis
Nepicastat
Posttraumatic Stress Disorder
Tizanidine
Spasticity
Diazepam
Epilepsy
SYN120
Parkinson's Disease Dementia (PDD)
Sinemet (carbidopa/levodopa)
Idiopathic Parkinson's Disease
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CVT-301 | Phase 3 | Idiopathic Parkinson's Disease | - | - |
dalfampridine-ER 7.5mg | Phase 3 | Post-Ischemic Stroke | - | - |
Fampridine-SR | Phase 3 | Multiple Sclerosis | - | - |
Dalfampridine-ER 5mg | Phase 3 | Multiple Sclerosis | - | - |
CVT-301 Low Dose | Phase 3 | Idiopathic Parkinson's Disease | - | - |
Fampridine-SR b.i.d. (Twice Daily) | Phase 3 | Multiple Sclerosis | - | - |
Dalfampridine Pill | Phase 3 | Multiple Sclerosis | - | - |
Dalfampridine | Phase 2 | Spinal Cord Injury | - | - |
10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP) | Phase 2 | Multiple Sclerosis | - | - |
Nepicastat | Phase 2 | Posttraumatic Stress Disorder | - | - |
Tizanidine | Phase 2 | Spasticity | - | - |
Diazepam | Phase 2 | Epilepsy | - | - |
SYN120 | Phase 2 | Parkinson's Disease Dementia (PDD) | - | - |
Sinemet (carbidopa/levodopa) | Phase 2 | Idiopathic Parkinson's Disease | - | - |
Frequently asked questions
What is in Acorda Therapeutics's drug pipeline?→
CatalystAlert tracks 14 drug candidates in Acorda Therapeutics's (ACOR) pipeline across Phase 3, Phase 2. Its lead program is CVT-301 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Acorda Therapeutics's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Acorda Therapeutics (ACOR) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ACOR biotech catalysts?→
Add ACOR to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Acorda Therapeutics's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.